Patent classifications
A61K35/63
Biologically active food supplement
A biologically active food additive comprises an ecdysteroid medicinal herb, such as Rhaponticum carthamoides (5-70 wt. %), drone brood (1-70 wt. %), ascorbic acid (3.6-70 wt. %), vitamin E (0.05-30 wt. %), and vehicles, such as calcium stearate, talc, lactose (the balance). The additive contributes to increasing the muscle weight in athletes, maintaining testosterone level, and demonstrates anabolic, anticatabolic and potency enhancing effects.
Biologically active food supplement
A biologically active food additive comprises an ecdysteroid medicinal herb, such as Rhaponticum carthamoides (5-70 wt. %), drone brood (1-70 wt. %), ascorbic acid (3.6-70 wt. %), vitamin E (0.05-30 wt. %), and vehicles, such as calcium stearate, talc, lactose (the balance). The additive contributes to increasing the muscle weight in athletes, maintaining testosterone level, and demonstrates anabolic, anticatabolic and potency enhancing effects.
HONEY FRACTION
The present invention provides a honey fraction obtainable by a method comprising (a) obtaining an absorbed component by causing honey to be brought into contact with an adsorbent, (b) obtaining an organic solvent fraction by eluting the absorbed component with an organic solvent that is acetone, ethyl acetate, or ethanol, and (c) obtaining a honey fraction from the organic solvent fraction.
Method of treating androgen deficiency in women
- Dmitriy G. Elistratov ,
- Villory I. Strukov ,
- Vyacheslav N. Trifonov ,
- Yuliya A. Elistratova ,
- Konstantin G. Elistratov ,
- Natalia V. Kurus′ ,
- Alexander V. Fyodorov ,
- Evgeniy N. Krutyakov ,
- Elena S. Andreyeva ,
- Tatiana V. Elistratova ,
- Irina V. Khomyakova ,
- Galina A. Tolbina ,
- Galina V. Dolgushkina ,
- Alla N. Astafieva ,
- Tatiana A. Kuptsova ,
- Yuliya G. Shcherbakova ,
- Natalia M. Smirnova
A biologically active food additive, comprising drone brood homogenate in the daily amount between 10 and 600 mg which can be combined on the weight percent basis with a calcium compound selected from calcium carbonate, calcium citrate, calcium gluconate, calcium aspartate, calcium phosphate and calcium citrate 16.67 to 93.75 wt. %; and drone brood 6.25 to 83.33 wt. %. Trials showed that administering the preparation contributes to the normalization of androgens in women resulting in the overall health improvement and disappearance or decrease of clinical signs of androgen deficiency.
Method of treating androgen deficiency in women
- Dmitriy G. Elistratov ,
- Villory I. Strukov ,
- Vyacheslav N. Trifonov ,
- Yuliya A. Elistratova ,
- Konstantin G. Elistratov ,
- Natalia V. Kurus′ ,
- Alexander V. Fyodorov ,
- Evgeniy N. Krutyakov ,
- Elena S. Andreyeva ,
- Tatiana V. Elistratova ,
- Irina V. Khomyakova ,
- Galina A. Tolbina ,
- Galina V. Dolgushkina ,
- Alla N. Astafieva ,
- Tatiana A. Kuptsova ,
- Yuliya G. Shcherbakova ,
- Natalia M. Smirnova
A biologically active food additive, comprising drone brood homogenate in the daily amount between 10 and 600 mg which can be combined on the weight percent basis with a calcium compound selected from calcium carbonate, calcium citrate, calcium gluconate, calcium aspartate, calcium phosphate and calcium citrate 16.67 to 93.75 wt. %; and drone brood 6.25 to 83.33 wt. %. Trials showed that administering the preparation contributes to the normalization of androgens in women resulting in the overall health improvement and disappearance or decrease of clinical signs of androgen deficiency.
Glucagon-like-peptide-2 (GLP-2) analogues
GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
Glucagon-like-peptide-2 (GLP-2) analogues
GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
Pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity
The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance
Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.
Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance
Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.